Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease
Open accessThe DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index.
Abstract
Heterozygous mutations in GBA1, the gene encoding lysosomal glucocerebrosidase, are the most frequent known genetic risk factor for Parkinson's disease. Reduced glucocerebrosidase and α-synuclein accumulation are directly related in cell models of Parkinson's disease. We investigated relationships between Parkinson's disease-specific glucocerebrosidase deficits, glucocerebrosidase-related pathways, and α-synuclein levels in brain tissue from subjects with sporadic Parkinson's disease without GBA1 mutations. Brain regions with and without a Parkinson's disease-related increase in α-synuclein levels were assessed in autopsy samples from subjects with sporadic Parkinson's disease (n = 19) and age- and post-mortem delay-matched controls (n = 10). Levels of glucocerebrosidase, α-synuclein and related lysosomal and autophagic proteins were assessed by western blotting. Glucocerebrosidase enzyme activity was measured using a fluorimetric assay, and glucocerebrosidase and α-synuclein messenger RNA expression determined by quantitative polymerase chain reaction. Related sphingolipids were analysed by mass spectrometry. Multivariate statistical analyses were performed to identify differences between disease groups and regions, with non-parametric correlations used to identify relationships between variables. Glucocerebrosidase protein levels and enzyme activity were selectively reduced in the early stages of Parkinson's disease in regions with increased α-synuclein levels although limited inclusion formation, whereas GBA1 messenger RNA expression was non-selectively reduced in Parkinson's disease. The selective loss of lysosomal glucocerebrosidase was directly related to reduced lysosomal chaperone-mediated autophagy, increased α-synuclein and decreased ceramide. Glucocerebrosidase deficits in sporadic Parkinson's disease are related to the abnormal accumulation of α-synuclein and are associated with substantial alterations in lysosomal chaperone-mediated autophagy pathways and lipid metabolism. Our data suggest that the early selective Parkinson's disease changes are likely a result of the redistribution of cellular membrane proteins leading to a chronic reduction in lysosome function in brain regions vulnerable to Parkinson's disease pathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, loss‐of‐function mutations in GBA disrupt the autophagic flux and lead to the aggregation of SNCA/α‐synuclein (Murphy et al, 2014).”
From Autophagy in major human diseases (2021) · cites this paper as Murphy et al, 2014
Citations
Cites
1 retracted
Crews, L., Spencer, B., Desplats, P., Patrick, C., Paulino, A., Rockenstein, E., Hansen, L., Adame, A., Galasko, D., & Masliah, E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009313 · Cited by 367
RetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
How to Interpret LC3 Immunoblotting
Mizushima, N., & Yoshimori, T. (2007) · Autophagy · doi:10.4161/auto.4600 · Cited by 2,669
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Self-citationImpaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024
Morris, J. C. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004870 · Cited by 1,641
Lysosomal membrane permeabilization in cell death
Boya, P., & Kroemer, G. (2008) · Oncogene · doi:10.1038/onc.2008.310 · Cited by 1,426
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Self-citation
Research works printed but not linked: 1
- Stone, 2000, Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease, Hum Mutat, 15, 181, 10.1002/(SICI)1098-1004(200002)15:2<181::AID-HUMU7>3.0.CO;2-S · DOI · Paper page
Cited by
Items 301–400 of 475
Zhuo, Y., Li, X., He, Z., & Lu, M. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03280-0 · Cited by 19
Ratan, Y., Rajput, A., Pareek, A., Pareek, A., Jain, V. K., Sonia, S., Farooqui, Z., Kaur, R., & Singh, G. (2024) · Biomolecules · doi:10.3390/biom14010073 · Cited by 21
Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia
Lee, J. Y., Marian, O. C., & Don, A. S. (2021) · NeuroMolecular Medicine · doi:10.1007/s12017-021-08644-4 · Cited by 20
Trends in glycolipid biomarker discovery in neurodegenerative disorders by mass spectrometry
Dehelean, L., Sarbu, M., Petrut, A., & Zamfir, A. D. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-15950-4_42 · Cited by 16
Role of Lipids in the Pathogenesis of Parkinson’s Disease
Kamano, S., Ozawa, D., Ikenaka, K., & Nagai, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168935 · Cited by 16
“In addition, lysosomal enzymes show high activity in the substantia nigra, and decreases in these activities have been noted in PD/DLB patients and in older individuals [144,145].”
BackgroundMitochondrial dysfunction, cause or consequence in neurodegenerative diseases?
Acker, Z. P. V., Leroy, T., & Annaert, W. G. (2024) · BioEssays · doi:10.1002/bies.202400023 · Cited by 21
Clarke, E., Jantrachotechatchawan, C., Buhidma, Y., Broadstock, M., Yu, L., Howlett, D. R., Aarsland, D., Ballard, C. G., & Francis, P. T. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104502 · Cited by 16
Senkevich, K. A., Kopytova, A. E., Usenko, T. S., Emelyanov, A., & Pchelina, S. (2021) · Acta Naturae · doi:10.32607/actanaturae.11031 · Cited by 21
Kim, J. J., Daadi, E. W., Oh, T. T., Daadi, E. S., & Daadi, M. M. (2022) · Genes · doi:10.3390/genes13111937 · Cited by 14
Trivedi, V. S., Magnusen, A. F., Rani, R., Marsili, L., Slavotinek, A. M., Prows, D. R., Hopkin, R. J., McKay, M. A., & Pandey, M. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214340 · Cited by 17
The role of sphingosine-1-phosphate in the development and progression of Parkinson’s disease
Wang, W., Zhao, Y., & Zhu, G. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1288437 · Cited by 17
Canonical and noncanonical autophagy: involvement in Parkinson’s disease
Sakurai, M., & Kuwahara, T. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1518991 · Cited by 17
Sirtuins and Proteolytic Systems: Implications for Pathogenesis of Synucleinopathies
Sampaio‐Marques, B., & Ludovico, P. (2015) · Biomolecules · doi:10.3390/biom5020735 · Cited by 16
Perez‐Roca, L., Adame-Castillo, C., Campdelacreu, J., Ispierto, L., Vilas, D., Reñé, R., Álvarez, R., Gascón‐Bayarri, J., Serrano-Muñoz, M. A., Ariza, A., et al. (2018) · Aging and Disease · doi:10.14336/ad.2017.0505 · Cited by 15
“Analyses of GCase activity and expression levels in PD brains have shown that GCase activity and protein levels are diminished in sporadic PD with and without GBA mutations [12, 13].”
BackgroundInduced Pluripotent Stem Cell Modeling of Gaucher’s Disease: What Have We Learned?
Santos, D., & Tiscórnia, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040888 · Cited by 17
Deconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purpose
Li, J., Li, S., Zhang, L., Ouyang, L., & Liu, B. (2015) · Oncotarget · doi:10.18632/oncotarget.5803 · Cited by 18
“However, there is no evidence so far indicating connections between GBA mutations and macroautophagy [110].”
BackgroundPeng, Y., Liou, B., Lin, Y., Mayhew, C. N., Fleming, S. M., & Sun, Y. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.03.007 · Cited by 14
Su, H., Masters, C. L., Bush, A. I., Barnham, K. J., Reid, G. E., & Vella, L. J. (2023) · PROTEOMICS · doi:10.1002/pmic.202300063 · Cited by 14
“Extensive evidence suggests altered lipid metabolism and abnormal activity of lipid-regulating enzymes in the context of neurological disorders, including AD [45–51], Parkinson’s disease [87–92]; fron-totemporal dementia [93]; multiple sclerosis (MuS) [43, 94], and Lewy body disorders (LBD) [44].”
Backgroundde Almeida, M. F., Chaves, R. S., Silva, C. M., Chaves, J. C. S., de Melo, K. P., & Ferrari, M. (2016) · IBRO Reports · doi:10.1016/j.ibror.2016.08.001 · Cited by 14
“Several recently published studies confirmed the accuracy of Neu-N levels, measured by Western blot, alone or comparedwith immunolabeled neurons or caspase 3 levels, to infer about cell loss (Zhang et al., 2013; Murphy et al., 2014; Cheng et al., 2015; Wang et al., 2015).”
ResultStatus and future directions of clinical trials in Parkinson's disease
Söderbom, G. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.02.009 · Cited by 15
Hatton, S. L., & Pandey, M. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031089 · Cited by 17
Substrate Reduction Therapy for GBA1‐Associated Parkinsonism: Are We Betting on the Wrong Mouse?
Sidransky, E., Arkadir, D., Bauer, P., Dinur, T., Lopez, G. J., Rolfs, A., & Zimran, A. (2019) · Movement Disorders · doi:10.1002/mds.27903 · Cited by 14
Self-citationHiggins, A., Toffoli, M., Mullin, S., Lee, C., Koletsi, S., Avenali, M., Blandini, F., & Schapira, A. H. V. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2021-0032 · Cited by 13
Liang, M., Chen, L., He, Q., Mi, X., Qu, L., Xie, J., & Song, N. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121508 · Cited by 15
Usenko, T. S., Timofeeva, A., Beletskaia, M., Basharova, K. S., Baydakova, G., Bezrukova, A. I., Grunina, M. N., Emelyanov, A., Miliukhina, I. V., Zakharova, E. Y., et al. (2024) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2301016 · Cited by 12
GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds
Brockmann, K. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.562522 · Cited by 13
“…tissue and IPS cell-derived neurons show that reduced lysosomal GCase activity is paralleled by increased levels of alpha-synuclein, not only in PDGBA but, to a lesser degree, also in cases with PDGBA_wild type (Gegg et al., 2012; Murphy et al., 2014; Schondorf et al., 2014; Moors et al., 2019).”
BackgroundGlucocerebrosidase expression patterns in the non-human primate brain
Dopeso‐Reyes, I. G., Sucunza, D., Rico, A. J., Pignataro, D., Marín-Ramos, D., Roda, E., Rodriguez-Perez, A. I., Labandeira-García, J. L., & Lanciego, J. L. (2017) · Brain Structure and Function · doi:10.1007/s00429-017-1504-1 · Cited by 15
“…function and dysfunction, ER stress and cytotoxicity that all together would be the actors truly sustaining the aggregation of misfolded alpha-synuclein (Wong et al. 2004; Mazzuli et al. 2011; Kurawa-Akanbi et al. 2012; Murphy et al. 2014; Chiasserini et al. 2015; Gegg and Schapira 2016).”
BackgroundRyan, E., Seehra, G., & Sidransky, E. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.08.006 · Cited by 13
Self-citationCognition as a mediator for gait and balance impairments in GBA-related Parkinson’s disease
Morris, R., Martini, D. N., Ramsey, K., Kelly, V. E., Smulders, K., Hiller, A., Chung, K. A., Hu, S., Zabetian, C. P., Poston, K. L., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00344-5 · Cited by 12
Ambroxol: A potential therapeutics against neurodegeneration
Dhanve, P., Aggarwal, P., Choure, S., Dhaked, D. K., & Banerjee, S. (2023) · Health Sciences Review · doi:10.1016/j.hsr.2023.100096 · Cited by 15
Burbulla, L. F., Zheng, J., Song, P., Jiang, W., Johnson, M., Brundin, P., & Krainc, D. (2021) · JCI Insight · doi:10.1172/jci.insight.148649 · Cited by 16
Lee, C., Menozzi, E., Chau, K., & Schapira, A. H. V. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15524 · Cited by 12
“…that arise from a mutation in lysosomal enzymes that metabolise lipids harbour an increased risk of developing PD (Robak et al., 2017), and in those patients that develop PD, accumulation of lipids are associated with alpha- synuclein accumulation (Nelson et al., 2014; Smith et al., 2014).”
Backgroundα-Synuclein in Parkinson's Disease: 12 Years Later
Vekrellis, K., Emmanouilidou, E., Xilouri, M., & Stefanis, L. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041645 · Cited by 16
Human Brain Lipidomics: Investigation of Formalin Fixed Brains
Beger, A. W., Hauther, K. A., Dudzik, B., Woltjer, R. L., & Wood, P. L. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.835628 · Cited by 11
Genetic mechanism vs genetic subtypes: The example of GBA
Senkevich, K. A., Rudakou, U., & Gan‐Or, Z. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00016-3 · Cited by 12
GBA1-and LRRK2-directed Treatments: The Way Forward
Eshed, G. M., & Alcalay, R. N. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.106039 · Cited by 10
Okai, T., Sato, S., Deshpande, M., Matsumoto, S.-I., Nakayama, M., Yamamoto, S., Strack-Logue, B., Hioki, T., Tanaka, M., & Proetzel, G. (2025) · PLoS ONE · doi:10.1371/journal.pone.0321145 · Cited by 15
“In idiopathic PD patients reduced GCase activity has also been reported independent from the GBA1 mutation status and it is thought that lysosomal dysfunction and age-related diminished lysosomal capacity contribute to the accumulation of α -synuclein [81,82,87].”
Lanore, A., Lesage, S., Mariani, L., Menon, P. J., Ravassard, P., Cheval, H., Corti, O., Brice, A., & Corvol, J. (2022) · Genes · doi:10.3390/genes13030479 · Cited by 11
“Post-mortem brain analysis revealed a decrease in GCase protein level and activity with increased α-Syn levels in PD patients compared to controls [40].”
BackgroundInfluentialRole of rodent models in advancing precision medicine for Parkinson's disease
Simons, E., & Fleming, S. M. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00002-3 · Cited by 13
Shen, H., Yu, Y., Wang, J., Nie, Y., Tang, Y., & Qu, M. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01585-7 · Cited by 11
Glucocerebrosidase dysfunction in neurodegenerative disease
Brooker, S. M., & Krainc, D. (2021) · Essays in Biochemistry · doi:10.1042/ebc20210018 · Cited by 13
Ghrelin alleviates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells
Xue, Y., He, X., Yuan, W., Yang, C., Zhu, L., Liu, F., & Feng, J. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.314314 · Cited by 13
“In addition, at both the mRNA and protein levels, α-synuclein expression is increased in sporadic PD brains (Murphy et al., 2014).”
BackgroundFujiwara, Y., Kabuta, C., Sano, T., Murayama, S., Saito, Y., & Kabuta, T. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105243 · Cited by 11
Labrador‐Garrido, A., Zhong, S., Hughes, L. P., Keshiya, S., Kim, W. S., Halliday, G. M., & Dzamko, N. L. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1229213 · Cited by 9
Self-citationParnetti, L., Eusebi, P., & Lleó, A. (2016) · Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences · doi:10.1159/000445452 · Cited by 12
Are Proteinopathy and Oxidative Stress Two Sides of the Same Coin?
Mehta, N. J., Marwah, P. K., & Njus, D. (2019) · Cells · doi:10.3390/cells8010059 · Cited by 12
Changes in plasma arylsulfatase A level as a compensatory biomarker of early Parkinson’s disease
Yoo, H. S., Lee, J. S., Chung, S. J., Ye, B. S., Sohn, Y. H., Lee, S., & Lee, P. H. (2020) · Scientific Reports · doi:10.1038/s41598-020-62536-4 · Cited by 10
Akiyama, T., Sato, S., Ko, S. B. H., Sano, O., Sato, S., Saito, M., Nagai, H., Ko, M. S. H., & Iwata, H. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0302 · Cited by 10
Saposin C, Key Regulator in the Alpha-Synuclein Degradation Mediated by Lysosome
Ruz, C., Barrero, F. J., Pelegrina, J., Bandrés‐Ciga, S., Vives, F., & Durán, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231912004 · Cited by 9
“[13] corroborated these results, demonstrating that there was a deficit of β-GCase activity in the brain of patients with sporadic PD, being responsible for the accumulation of α-Syn and alterations in lipid metabolism.”
BackgroundResultFragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase
Palmer, N., Agnew, C., Benn, C., Buffham, W. J., Castro, J. N., Chessari, G., Clark, M., Cons, B. D., Coyle, J. E., Dawson, L. A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00702 · Cited by 9
Synaptic and cognitive impairment associated with L444P heterozygous glucocerebrosidase mutation
Lado, W. E., Ham, A., Li, H., Zhang, H., Chang, A. Y., Sardi, S. P., Alcalay, R. N., Arancio, O., Przedborski, S., & Tang, G. (2024) · Brain · doi:10.1093/brain/awae380 · Cited by 8
Precision Medicine in Parkinson’s Disease
Eshed, G. M., & Alcalay, R. N. (2025) · Neurologic Clinics · doi:10.1016/j.ncl.2024.12.011 · Cited by 8
Acidic Ca2+ Stores in Neurodegeneration
Lloyd‐Evans, E. (2016) · Messenger · doi:10.1166/msr.2016.1054 · Cited by 9
Polissidis, A., Koronaiou, E., Nikolopoulou, G. B., Viel, C., Nikatou, M., Bogiongko, M., Sardi, S. P., Xilouri, M., Vekrellis, K., & Stefanis, L. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105612 · Cited by 10
Dobert, J. P., Bub, S., Mächtel, R., Januliene, D., Steger, L., Regensburger, M., Wilfling, S., Chen, J., Dejung, M., Plötz, S., et al. (2024) · Advanced Science · doi:10.1002/advs.202401641 · Cited by 12
Arylsulphatase A activity in familial parkinsonism: a pathogenetic role?
Antelmi, E., Rizzo, G., Fabbri, M., Capellari, S., Scaglione, C. L. M., & Martinelli, P. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7425-5 · Cited by 9
“Indeed, this hypothesis has been recently strengthened by the finding that GBA activity appeared to be reduced even in the CSF of PD patients when compared to controls [40] and by the anatomopathological finding that GBA activity was reduced even in patients without the mutation and it is directly linked to the abnorm…”
ResultBehavioral Phenotyping in a Murine Model of GBA1-Associated Parkinson Disease
Do, J., Perez, G., Berhe, B. A., Tayebi, N., & Sidransky, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136826 · Cited by 12
“Furthermore, even patients with idiopathic PD were found to have lowered GCase levels in post-mortem samples, suggesting a correlation between GCase deficiency and PD [12].”
BackgroundSelf-citationElmatboly, A. M., Sherif, A., Deeb, D. A., Benmelouka, A. Y., Bin-Jumah, M. N., Aleya, L., & Abdel‐Daim, M. M. (2020) · Environmental Science and Pollution Research · doi:10.1007/s11356-020-07914-1 · Cited by 11
“Genome-wide association studies (GWASs) (Dehay et al. 2012; Gleich et al. 2013; Usenovic et al. 2013; Gan-Or et al. 2013; Korvatska et al. 2013; Gonzalez et al. 2014; Murphy et al. 2014; Perrotta et al. 2015; Lesage et al. 2016; Abeliovich and Gitler 2016; Jinn e t a l .”
BackgroundPanunggal, B., Yeh, T., Tsao, S., Pan, C., Shih, W.-T., Lin, Y., Faradina, A., Fang, C., Huang, H.-Y., & Huang, S. (2025) · Aging · doi:10.18632/aging.206181 · Cited by 9
“Changes in lipid metabolism are increasingly recognized as playing a role in the development of Parkinson’s disease (PD), affecting motor function [51].”
Franck, L., Hahnefeld, L., Valek, L., Klatt‐Schreiner, K., Wilken‐Schmitz, A., Alnouri, M. W., Trautmann, S., Weyer, M.-P., Thomas, D., Gurke, R., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01114-9 · Cited by 8
“Increased ceramides in HT22 neurons upon ingestion of pre-formed α Syn fi brils Mutant GBA1 and α Syn mutually increase neuronal damage likely converging on lysosomal collapse 22,50 and mitochondrial toxicity 36 .”
Rodent models based on endolysosomal genes involved in Parkinson's disease
Sanchiz-Calvo, M., Bentea, E., & Baekelandt, V. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.09.004 · Cited by 8
Kim, M. J., Kim, S., Reinheckel, T., & Krainc, D. (2024) · JCI Insight · doi:10.1172/jci.insight.169594 · Cited by 8
Flow Cytometry Measurement of Glucocerebrosidase Activity in Human Monocytes
Hughes, L. P., Halliday, G. M., & Dzamko, N. L. (2020) · BIO-PROTOCOL · doi:10.21769/bioprotoc.3572 · Cited by 8
“…(Neumann et al., 2009; Sidransky et al., 2009; Lesage et al., 2011), reduced GCase activity is also observed in PD patients without GBA1 mutations (Murphy et al., 2014; Alcalay et al., 2015; Atashrazm et al., 2018), and there is increasing evidence supporting the notion that restoring GCase…”
BackgroundSelf-citationYang, W., Li, X., & Yin, N. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135093 · Cited by 8
Glucocerebrosidase variant T369M is not a risk factor for Parkinson’s disease in Sweden
Ran, C., Brodin, L., Gellhaar, S., Westerlund, M., Fardell, C., Nissbrandt, H., Söderkvist, P., Sydow, O., Markaki, I., Hertz, E., et al. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136767 · Cited by 11
Glucocerebrosidase and parkinsonism: lessons to learn
Marković, I., Kresojević, N. D., & Kostić, V. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8085-4 · Cited by 9
Alpha-synuclein inclusions reduced by PIKfyve inhibition in Parkinson disease cell models
Pozo, S. L. D., Uras, G., Fierli, F., Lentini, V., Koletsi, S., Lazaro-Hernandez, C., Chau, K., Hughes, D. A., & Schapira, A. H. V. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107053 · Cited by 8
Abubakar, M., Alom, S., Ali, F., Ali, S. R., Adhikary, K., Sarika, S., Gupta, P. K., Puppala, E. R., Murti, K., Nand, S., et al. (2026) · Current Neuropharmacology · doi:10.2174/011570159x446831260303200516 · Cited by 9
“GBA dysfunction may result from the buildup and aggregation of α-syn, since in the initial stages of PD, GBA protein amounts and function are decreased exclusively in brain areas wherein α-syn levels are substantially elevated [205].”
Sawangareetrakul, P., Ngiwsara, L., Champattanachai, V., Chokchaichamnankit, D., Saharat, K., Cairns, J. R. K., Srisomsap, C., Khwanraj, K., Dharmasaroja, P., Pulkes, T., et al. (2021) · Biomedical Reports · doi:10.3892/br.2021.1412 · Cited by 7
Arnaldo, L., Urbizu, A., Serradell, M., Gaig, C., Anillo, A., Gea, M., Vilas, D., Ispierto, L., Lopetegi, A. M., Mayà, G., et al. (2023) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2023.105832 · Cited by 7
Rademacher, D. J., Exline, J. E., & Foecking, E. M. (2025) · Biomedicines · doi:10.3390/biomedicines13061400 · Cited by 10
“Reduced GCase activity has been observed in the SNpc of PD patients [139] and has been reported to be more evident at the earlier PD stages [140].”
Dzamko, N. L. (2026) · CNS Drugs · doi:10.1007/s40263-026-01275-y · Cited by 7
What can pediatricians learn from adult inherited metabolic diseases?
Mochel, F. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12729 · Cited by 6
Mitochondria–lysosome crosstalk in GBA1-associated Parkinson’s disease
Sahyadri, M., Nadiga, A. P. R., Mehdi, S., Mruthunjaya, K., Nayak, P. G., Parihar, V. K., & Manjula, S. N. (2022) · 3 Biotech · doi:10.1007/s13205-022-03261-9 · Cited by 6
Lysosomes, autophagosomes and Alzheimer pathology in dementia with Lewy body disease
Gurney, R., Davidson, Y. S., Robinson, A., Richardson, A. M. T., Jones, M. S., Snowden, J. S., & Mann, D. M. A. (2018) · Neuropathology · doi:10.1111/neup.12472 · Cited by 6
“On the other hand, Murphy and coworkers found no changes in LAMP-1 in a group of PD and PDD patients at Braak PD stage V or less.(38) However, in a later study, as we have found here, the same authors reported decreased levels of LAMP-2, specifically LAMP-2A, in CG in the same patients featured in the earlier study, t…”
ResultPathways of protein synthesis and degradation in PD pathogenesis
Langston, R. G., & Cookson, M. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2020.01.002 · Cited by 9
Effect of Nutrient Availability on Progenitor Cells in Zebrafish (Danio Rerio)
Benítez-Santana, T., Simion, M., Corraze, G. R., Médale, F., & Joly, J. (2016) · Developmental Neurobiology · doi:10.1002/dneu.22406 · Cited by 7
“This results in impaired motor and cognitive functions, such as attention deficit disorder, learning and memory abilities, and neurodegenerative diseases (GilletteGuyonnet et al., 2013; Berrocal-Zaragoza et al., 2014; Murphy et al., 2014; Akitake et al, 2015).”
BackgroundClinical Studies of GBA1 -associated Parkinsonism: Progress and Challenges
Lopez, G. J., Monestime, G. M., & Sidransky, E. (2016) · Neurodegenerative Disease Management · doi:10.2217/nmt.15.68 · Cited by 6
Self-citationFomin, M., Zapf, K., Schieffer, E., Freitag, J., Bange, G., & Schieffer, B. (2026) · Inflammation Research · doi:10.1007/s00011-026-02283-w · Cited by 6
Liu, X., Liu, X., Liu, Y., Yang, B. K., Li, Y., Li, F., Qian, K., Liu, X., Xiao, L., Cui, G., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70082 · Cited by 8
Rodrigues, P. S., & Kale, P. P. (2021) · Revue Neurologique · doi:10.1016/j.neurol.2021.01.015 · Cited by 5
Benz, J., Rufer, A. C., Huber, S., Ehler, A., Hug, M. N., Topp, A., Guba, W., Hofmann, E. C., Jagasia, R., & Sarmiento, R. M. R. (2020) · Angewandte Chemie · doi:10.1002/ange.202013890 · Cited by 5
Lipids and Their Role in Aging and Neurodegenerative Decline
Bora, J., Lata, S., Mondal, S., Priya, S., Veettil, D. T., Malik, S., & Sreejith, P. (2026) · Lipidology · doi:10.3390/lipidology3010006 · Cited by 5
“Interestingly, decreased GCase activity has been observed in postmortem tissues from spontaneous PD patients lacking GBA mutations, although impaired lipid metabolism would be anticipated primarily in PD patients who are carriers of GBA mutations [123].”
Mazzetti, S., Contaldi, E., Basellini, M. J., Novello, C., Calogero, A. M., Straniero, L., Garrì, F., Ferri, V., Calandrella, D., Sorbo, F. D., et al. (2024) · Brain Pathology · doi:10.1111/bpa.13284 · Cited by 6
“We first checked for GCase staining in post-mortem human brains (Supplementary Figure S1) and found that it decreased in iPD patients compared to controls, as previously reported [40], and localized also at the synapses.”
Panagaki, T., Randi, E. B., Szabó, C., & Hölscher, C. (2023) · Journal of Parkinson s Disease · doi:10.3233/jpd-230030 · Cited by 7
Skin α‐Synuclein Seeding Activity in Patients with Type 1 Gaucher Disease
LoPiccolo, M. K., Wang, Z., Eshed, G. M., Fierro, L., Stauffer, C., Wang, K., Zhang, J., Tatsuoka, C. M., Balwani, M., Zou, W., et al. (2024) · Movement Disorders · doi:10.1002/mds.29935 · Cited by 4
“21,22 Moreover, GCase activity in neurons has been shown to decline with age in healthy adults, thus lowering the threshold to develop PD. 20,23 Thus, the association between positive skin α Syn seeding activity and age is not unexpected.”
Ciccaldo, M., Pérez‐Carmona, N., Piovesana, E., Cano‐Crespo, S., Ruano, A., Delgado, A., Fregno, I., Guzmán, B. C., Bellotto, M., Molinari, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-02346-8 · Cited by 4
“Noteworthy, lysosomal GCase malfunction appears to occur also in the idiopathic Parkinson brain 18 and fibroblasts 19 .”
Lunghi, G., Pedroli, C., Tagliabue, I., Dobi, D., Ciampa, M. G., Mauri, L., Rouvière, L., Henriques, A., Callizot, N., Sonnino, S., et al. (2025) · Glycoconjugate Journal · doi:10.1007/s10719-025-10185-y · Cited by 5
Molecular profiling in Parkinsonian syndromes: CSF biomarkers
Paoletti, F. P., Gaetani, L., & Parnetti, L. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.03.002 · Cited by 5
Tratnjek, L., Glavan, G., Višnjar, T., & Živin, M. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13161 · Cited by 4
“Anti-neuronal nuclei (NeuN) antibody: clone A60; mouse; monoclonal; Millipore, Cat# MAB377; tested in immunofluorescence stainings, Western blot performed by Murphy et al. (2014).”
MethodGlucocerebrosidase regulators SCARB2 and TFEB are up-regulated in Lewy body disease brain
Perez‐Roca, L., Prada-Dacasa, P., Segú-Vergés, C., Gámez‐Valero, A., Serrano-Muñoz, M. A., dos Santos, C. M. P., & Beyer, K. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.05.034 · Cited by 5
Dementia and cognitive decline
Huq, A. J., Eratne, D., & Velakoulis, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99417-0.00006-9 · Cited by 4
Dysregulated metabolism of ceramides and glycosphingolipids in Parkinson’s disease
Peng, Y., Chen, S.-J., Li, J., Lin, C., & Kuo, C. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100955 · Cited by 7
“GCase deficiency, in particular, has been repeatedly demonstrated in brain tissue with Lewy pathology, as well as in CSF and blood from both GBA1 carriers and sporadic PD patients (7, 34 – 37).”
Henderson, M. J., Chen, T. C., Glasstetter, L. M., Chen, Y., Marugán, J., & Sidransky, E. (2025) · Movement Disorders · doi:10.1002/mds.70168 · Cited by 7
“41”
Self-citationExploring the intersecting paths between metabolic disorders and neurological manifestations
Eissa, N., Chkier, D., Ahmed, A., Attia, R. T., Zia, M., Beiram, R., & Sadek, B. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e44658 · Cited by 3
Early GCase activity is a predictor of long-term cognitive decline in Parkinson’s disease
Oftedal, L., Lange, J., Pedersen, K. F., Erga, A. H., Dalen, I., Tysnes, O., Alves, G. W., & Maple‐Grødem, J. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00373-x · Cited by 4
“In the brains of patients with PD, GCase dysfunction is paralleled by α-synuclein accumulation [5, 6].”
BackgroundBezrukova, A. I., Basharova, K. S., Baydakova, G., Zakharova, E. Y., Pchelina, S., & Usenko, T. S. (2024) · Biochemistry (Moscow) · doi:10.1134/s0006297924070113 · Cited by 5
“Apart from this, we assessed for the first time the effect of Torin 1 on the relative GCase enzyme level, activity of which is decreased in GBA1-PD and sPD [51-53].”
[Autophagy pathways and key drug targets in Parkinson's disease].
Ouyang, L., Zhang, L., & Liu, B. (2016) · PubMed · Cited by 4
Trends in Glucocerebrosides Research: A Systematic Review
Desplanque, M., Bonte, M.-A., Gressier, B., Devos, D., Chartier‐Harlin, M., & Bélarbi, K. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.558090 · Cited by 3
“…alterations in alpha-synuclein homeostasis, lysosomal chaperone-mediated autophagy and immunity pathways involved in Parkinson’s disease pathogenesis (Murphy et al., 2014; Kitatani et al., 2015; Aflaki et al., 2016; Pandey et al., 2017); and (iii) therapeutic strategies that were first considered…”
BackgroundAre Lysosomes Potential Therapeutic Targets for Parkinson’s Disease?
Petese, A., Cesaroni, V., Cerri, S., & Blandini, F. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210809123630 · Cited by 3
Metadata
- Authors
- Murphy, K. E., Gysbers, A. M., Abbott, S. K., Tayebi, N., Kim, W. S., Sidransky, E., Cooper, A., Garner, B., & Halliday, G. M.
- Affiliations
- UNSW Sydney (AU)
- Neuroscience Research Australia (AU)
- University of Wollongong (AU)
- National Institutes of Health (US)
- Garvan Institute of Medical Research (AU)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-28
- Volume
- 137
- Issue
- 3
- Pages
- 834-848
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC3927701
- OpenAlex
- W2144140825
- Cited by
- 475
- References
- 85
- Citations by year
- 2026: 24 · 2025: 25 · 2024: 37 · 2023: 31 · 2022: 39 · 2021: 52 · 2020: 54 · 2019: 49 · 2018: 30 · 2017: 34 · 2016: 42 · 2015: 42 · 2014: 15
- FWCI
- 29.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- Figshare (submittedVersion, cc-by)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism (R24AA012725, R28AA012725)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase, alpha-synuclein, GBA1, sporadic Parkinson's disease, lysosomal dysfunction, chaperone-mediated autophagy, ceramide, sphingolipids, early-stage Parkinson's disease, brain regions, inclusion formation
- MeSH terms
- Aged, Aged, 80 and over, Autophagy, Brain, Female, Glucosylceramidase, Humans, Lysosomes, Male, Mutation, Parkinson Disease, Cohort Studies, Up-Regulation, Case-Control Studies, Molecular Chaperones, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.